Want to see JP:4575 full AI Analyst Report?
CanBas Co., Ltd. (4575) AI Stock Analysis
CanBas Co., Ltd.
(TSE/TYO:4575)
The overall score of 44 reflects a high-risk profile. The dominant factor is the extremely weak financial performance, characterized by zero revenue, accelerating cash burn, and a rapidly depleting equity base, which poses a going-concern risk. Moderately positive technical trends provide some support, but the negative P/E ratio and lack of dividends offer no valuation cushion. The company's near-term viability is entirely dependent on securing additional financing.
CanBas Co., Ltd. (4575) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 14.76B
- Dividend Yield
- ―
- Average Volume (3M)
- 177.56K
- Price to Earnings (P/E)
- -11.3
- Beta (1Y)
- 0.83
- Revenue Growth
- ―
- EPS Growth
- -8.52%
- Country
- Japan
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CanBas Co., Ltd. Business Overview & Revenue Model
Company Description
CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating var...
CanBas Co., Ltd. Financial Statement Overview
Summary
Financial performance is critically weak. The company is pre-revenue with escalating operating losses (TTM EBIT -Â¥1.36B) and deeply negative gross profit. The balance sheet has no debt, but equity is eroding rapidly (TTM ROE ~-80%). Cash burn is accelerating (TTM OCF -Â¥1.42B) and is unsustainable without new funding. The overall financial trajectory is severely negative.
Income Statement
1Very NegativeBalance Sheet
35NegativeCash Flow
5Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -820.00M | -984.00M | -671.00M | -608.00M |
| EBITDA | -1.35B | -1.36B | -47.67M | 53.65M | -1.24B | -848.65M |
| Net Income | -1.31B | -1.31B | -1.16B | -1.21B | -1.24B | -855.58M |
Balance Sheet | ||||||
| Total Assets | 1.78B | 1.78B | 3.05B | 2.43B | 2.09B | 790.71M |
| Cash, Cash Equivalents and Short-Term Investments | 1.45B | 1.45B | 2.83B | 1.89B | 1.62B | 737.77M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 367.34M |
| Total Liabilities | 134.71M | 134.71M | 107.00M | 91.99M | 153.85M | 540.02M |
| Stockholders Equity | 1.64B | 1.64B | 2.94B | 2.34B | 1.93B | 250.69M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.42B | -771.45M | -1.28B | -1.40B | -719.81M |
| Operating Cash Flow | 0 | -1.42B | -771.45M | -1.28B | -1.40B | -719.81M |
| Investing Cash Flow | 0 | 0 | 122.00K | 0 | 0 | 182.00K |
| Financing Cash Flow | 0 | 0 | 1.75B | 1.54B | 2.27B | 282.75M |
CanBas Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4575, the sentiment is Negative. The current price of 749.00 is below the 20-day moving average (MA) of 756.65, below the 50-day MA of 770.88, and above the 200-day MA of 743.42, indicating a neutral trend. The MACD of -3.17 indicates Negative momentum. The RSI at 48.92 is Neutral, neither overbought nor oversold. The STOCH value of 69.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4575.
CanBas Co., Ltd. Peers Comparison
Overall Rating
JP:459348Neutral- JP:457544Neutral
JP:497842Neutral
JP:777442Neutral
JP:459940Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4593 | 48Neutral | JPY 37.00B | 55.04 | ― | ― | -47.32% | ― |
| JP:4575 | 44Neutral | JPY 14.81B | -11.28 | ― | ― | ― | -8.52% |
| JP:4978 | 42Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:7774 | 42Neutral | JPY 25.54B | -58.02 | ― | ― | 3.43% | -53.59% |
| JP:4599 | 40Underperform | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:7776 | 26Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4575 | CanBas Co., Ltd. | 749.00 | -54.00 | -6.72% | |
| JP:4593 | Healios KK | 273.00 | -221.00 | -44.74% | |
| JP:4599 | StemRIM Inc. | 139.00 | -134.00 | -49.08% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 629.00 | 153.00 | 32.14% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026